MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease

MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6, its investigational oral therapy for ...

Merry Life Biomedical Company, Ltd.: MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational ...

MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6 ...